|
Antitope in major alliance with UCB |
|
Written by News Desk
|
|
Wednesday, 19 December 2007 |
|
Cambridge-based biotech firm, Antitope Ltd, has struck a research collaboration with biopharm giant and Celltech acquisitor, UCB, where Antitope will apply EpiScreen™ technology to profile the immunogenicity of therapeutic monoclonal antibodies.
“We are very pleased to be working with UCB whom we recognise as a world-class company in the development and commercialisation of therapeutic antibodies,” said Dr Matthew Baker, chief scientific officer and co-founder of Antitope.
|